According to recent research, younger patients are at risk in losing life expectancy after TAVR operations using currently available valves. That’s why the success of DurAVR will save many lives and grow the market significantly.
Yonger patients have a higher than expected risk of mortality (death) 10 years after a mechanical or a tissue (bioprosthetic) valve replacement compared to what would be expected in the general population.1 Data suggests that at 10 years after surgery, 1 in 5 patients who undergoes a mechanical aortic valve replacement at 50 years of age has died or required a reoperation.
Not advice, DYOR!!!
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$5.91 |
Change
0.000(0.00%) |
Mkt cap ! $91.59M | |||
| Open | High | Low | Value | Volume |
| 0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 2103 | $5.86 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $6.00 | 1000 | 1 |
View Market Depth
| Last trade - 10.21am 27/06/2025 (20 minute delay) ? |
| AVR (ASX) Chart |
Day chart unavailable